Board of Directors:

VIJAY B. SAMANT (Chief Executive Officer, Director)

  • President and Chief Executive Officer, Vical Incorporated, 2000-2019 

  • Raised approx. $500M 

  • Chief Operating Officer, Merck Vaccine Division, 1998-2000 

  • Contributed to the development of Vaqta® (Hepatitis A vaccine), Varivax® (chickenpox vaccine), Liquid PedvaxHIB ® (Hib vaccine) and Comvax® (combination vaccine of Hib and hepatitis B), Zostavax® (shingles vaccine), Aldurazyme® (mucopolysaccharidosis I), and Procysbi® (nephropathic cystinosis)

BRIAN PUSCH, ESQ. (Secretary, Treasurer, Director)

  • Partner, Pusch & Gal (Funding/Financing Advisor to biopharma companies for 35 years)

  • Co-founder, Inozyme Pharma (NASDAQ:INZY IPO July 2020)

  • CEO, Microbes, Inc. (2012 to date)

  • Director, Kolltan Pharmaceuticals, Inc. (acquired by Celldex Therapeutics November 2014), EvrysBio, InvivoSciences, Inc., Opna-IO

  • Adviser, Plexxikon Inc. (acquired by Daiichi Sankyo April 2011)

  • Six successful exits ($500M-$6.8B)

LOUIS WEINER, MD (Director)*

  • Director, Georgetown Lombardi Comprehensive Cancer Center

  • Director, Medstar Georgetown Cancer Institute

  • Chair, Immunology Task Force, AACR

  • Chair, National Cancer Institute Board of Scientific Counselors

  • Past VP Translational Research, Fox Chase Cancer Institute

BRUCE CHABNER, MD (Director)* 

  • Director Emeritus Clinical Research, The Massachusetts General Hospital Cancer Center

  • Member, Executive Committee, Allen Distinguished Investigator, The Massachusetts General Hospital Cancer Center

  • Past Chair, National Cancer Institute Advisory Board

  • Recipient, US Public Health Service Distinguished Service Award

  • Senior Editor, The Oncologist

GABRIEL HORTOBAGYI, MD (Director)*

  • Professor & Chair Emeritus, Department of Breast Cancer Oncology, M.D. Anderson Cancer Center

  • Chair, Southwest Oncology Group Breast Committee

  • Member, Scientific Advisory Board, The Breast Cancer Research Foundation

  • Past President, ASCO

  • Chevalier, Ordre National de la Legion d’Honneur, France

*Will join the Board of Directors in conjunction with closing the Series A financing